INTRODUCTION: Mesenchymal-epithelial transition factor gene (MET) gene copy number gain may be a predictive biomarker for mesenchymal-epithelial transition factor (MET) inhibition in lung cancer, but the most appropriate method and criteria for defining MET positivity are uncertain. METHODS: MET copy number was assessed by fluorescence in situ hybridization in lung adenocarcinoma. Positivity criteria included mean MET per cell values greater than 5 (low [≥5 to <6], intermediate [≥6 to <7], and high [≥7]) and mean MET-to-chromosome 7 centromere ratios (MET/CEP7) of at least 1.8 (low [≥1.8 to ≤2.2], intermediate [>2.2 to <5], and high [≥5]). Associated clinical and molecular characteristics were captured. RESULTS: Of 686 cases, 99 (14%) had a mean MET per cell value of 5 or greater, 52 of 1164 (4.5%) had a MET/CEP7 ratio of 1.8 or higher. Other oncogenic drivers (in EGFR, KRAS, anaplastic lymphoma receptor tyrosine kinase gene [ALK], erb-b2 receptor tyrosine kinase 2 gene [ERBB2], BRAF, NRAS, ROS1, or ret proto-oncogene [RET]) were detectable in 56% of the group with a mean MET per cell value of 5 or higher and 47% of the group with a MET/CEP7 ratio of 1.8 or higher, suggesting that many MET-positive cases are not truly MET addicted. The rates of concomitant drivers in the groups of patients in the low, indeterminate, and high categories of mean MET per cell were 32 of 52 (62%), 12 of 19 (63%), and 11 of 27 (41%) (p = 0.2), and the rates of concomitant drivers in the low, intermediate, and high categories of MET/CEP7 ratios were 15 of 29 (52%), 9 of 18 (50%), and 0 of 4 (0%), respectively (p = 0.04). A MET/CEP7 ratio of 1.8 or higher in the absence of other oncogenes was associated with a higher rate of adrenal metastases (p = 0.03) but not with never-smoking status. CONCLUSIONS: A fluorescence in situ hybridization MET/CEP7 ratio of 5 or higher defined a "MET-positive" group with no oncogenic overlap. As this method and criteria are also associated with the highest response rate to MET inhibition, it represents the clearest definition of a MET copy number gain-addicted state. However, a MET-associated phenotype may also exist across cases with a MET/CEP7 of 1.8 or higher when no other oncogene overlap occurs.
INTRODUCTION: Mesenchymal-epithelial transition factor gene (MET) gene copy number gain may be a predictive biomarker for mesenchymal-epithelial transition factor (MET) inhibition in lung cancer, but the most appropriate method and criteria for defining MET positivity are uncertain. METHODS: MET copy number was assessed by fluorescence in situ hybridization in lung adenocarcinoma. Positivity criteria included mean MET per cell values greater than 5 (low [≥5 to <6], intermediate [≥6 to <7], and high [≥7]) and mean MET-to-chromosome 7 centromere ratios (MET/CEP7) of at least 1.8 (low [≥1.8 to ≤2.2], intermediate [>2.2 to <5], and high [≥5]). Associated clinical and molecular characteristics were captured. RESULTS: Of 686 cases, 99 (14%) had a mean MET per cell value of 5 or greater, 52 of 1164 (4.5%) had a MET/CEP7 ratio of 1.8 or higher. Other oncogenic drivers (in EGFR, KRAS, anaplastic lymphoma receptor tyrosine kinase gene [ALK], erb-b2 receptor tyrosine kinase 2 gene [ERBB2], BRAF, NRAS, ROS1, or ret proto-oncogene [RET]) were detectable in 56% of the group with a mean MET per cell value of 5 or higher and 47% of the group with a MET/CEP7 ratio of 1.8 or higher, suggesting that many MET-positive cases are not truly MET addicted. The rates of concomitant drivers in the groups of patients in the low, indeterminate, and high categories of mean MET per cell were 32 of 52 (62%), 12 of 19 (63%), and 11 of 27 (41%) (p = 0.2), and the rates of concomitant drivers in the low, intermediate, and high categories of MET/CEP7 ratios were 15 of 29 (52%), 9 of 18 (50%), and 0 of 4 (0%), respectively (p = 0.04). A MET/CEP7 ratio of 1.8 or higher in the absence of other oncogenes was associated with a higher rate of adrenal metastases (p = 0.03) but not with never-smoking status. CONCLUSIONS: A fluorescence in situ hybridization MET/CEP7 ratio of 5 or higher defined a "MET-positive" group with no oncogenic overlap. As this method and criteria are also associated with the highest response rate to MET inhibition, it represents the clearest definition of a MET copy number gain-addicted state. However, a MET-associated phenotype may also exist across cases with a MET/CEP7 of 1.8 or higher when no other oncogene overlap occurs.
Authors: Ermanno Gherardi; Mark E Youles; Ricardo N Miguel; Tom L Blundell; Luisa Iamele; Julian Gough; Abhishek Bandyopadhyay; Guido Hartmann; P Jonathan G Butler Journal: Proc Natl Acad Sci U S A Date: 2003-10-03 Impact factor: 11.205
Authors: Murugabaskar Balan; Eduardo Mier y Teran; Ana Maria Waaga-Gasser; Martin Gasser; Toni K Choueiri; Gordon Freeman; Soumitro Pal Journal: J Biol Chem Date: 2015-02-02 Impact factor: 5.157
Authors: Jamie E Chaft; Maria E Arcila; Paul K Paik; Christopher Lau; Gregory J Riely; M Catherine Pietanza; Maureen F Zakowski; Valerie Rusch; Camelia S Sima; Marc Ladanyi; Mark G Kris Journal: Mol Cancer Ther Date: 2011-12-01 Impact factor: 6.261
Authors: Lynette M Sholl; Dara L Aisner; Marileila Varella-Garcia; Lynne D Berry; Dora Dias-Santagata; Ignacio I Wistuba; Heidi Chen; Junya Fujimoto; Kelly Kugler; Wilbur A Franklin; A John Iafrate; Marc Ladanyi; Mark G Kris; Bruce E Johnson; Paul A Bunn; John D Minna; David J Kwiatkowski Journal: J Thorac Oncol Date: 2015-05 Impact factor: 15.609
Authors: D Ross Camidge; Scott A Kono; Antonella Flacco; Aik-Choon Tan; Robert C Doebele; Qing Zhou; Lucio Crino; Wilbur A Franklin; Marileila Varella-Garcia Journal: Clin Cancer Res Date: 2010-11-09 Impact factor: 12.531
Authors: D Ross Camidge; Yung-Jue Bang; Eunice L Kwak; A John Iafrate; Marileila Varella-Garcia; Stephen B Fox; Gregory J Riely; Benjamin Solomon; Sai-Hong I Ou; Dong-Wan Kim; Ravi Salgia; Panagiotis Fidias; Jeffrey A Engelman; Leena Gandhi; Pasi A Jänne; Daniel B Costa; Geoffrey I Shapiro; Patricia Lorusso; Katherine Ruffner; Patricia Stephenson; Yiyun Tang; Keith Wilner; Jeffrey W Clark; Alice T Shaw Journal: Lancet Oncol Date: 2012-09-04 Impact factor: 41.316
Authors: Kadoaki Ohashi; Lecia V Sequist; Maria E Arcila; Christine M Lovly; Xi Chen; Charles M Rudin; Teresa Moran; David Ross Camidge; Cindy L Vnencak-Jones; Lynne Berry; Yumei Pan; Hidefumi Sasaki; Jeffrey A Engelman; Edward B Garon; Steven M Dubinett; Wilbur A Franklin; Gregory J Riely; Martin L Sos; Mark G Kris; Dora Dias-Santagata; Marc Ladanyi; Paul A Bunn; William Pao Journal: Clin Cancer Res Date: 2013-03-20 Impact factor: 12.531
Authors: Tejas Patil; Rao Mushtaq; Sydney Marsh; Christine Azelby; Miheer Pujara; Kurtis D Davies; Dara L Aisner; William T Purcell; Erin L Schenk; Jose M Pacheco; Paul A Bunn; D Ross Camidge; Robert C Doebele Journal: Clin Lung Cancer Date: 2019-11-21 Impact factor: 4.785
Authors: Mark M Awad; Giulia C Leonardi; Sasha Kravets; Suzanne E Dahlberg; Alexander Drilon; Sinead A Noonan; D Ross Camidge; Sai-Hong I Ou; Daniel B Costa; Shirish M Gadgeel; Conor E Steuer; Patrick M Forde; Viola W Zhu; Yoko Fukuda; Jeffrey W Clark; Pasi A Jänne; Tony Mok; Lynette M Sholl; Rebecca S Heist Journal: Lung Cancer Date: 2019-05-11 Impact factor: 5.705
Authors: Alessandro Russo; Ana Rita Lopes; Michael G McCusker; Sandra Gimenez Garrigues; Giuseppina R Ricciardi; Katherine E Arensmeyer; Katherine A Scilla; Ranee Mehra; Christian Rolfo Journal: Curr Oncol Rep Date: 2020-04-16 Impact factor: 5.075
Authors: Matthew A Smith; Thomas Licata; Aliya Lakhani; Marileila Varella Garcia; Hans-Ulrich Schildhaus; Vincent Vuaroqueaux; Balazs Halmos; Alain C Borczuk; Y Ann Chen; Benjamin C Creelan; Theresa A Boyle; Eric B Haura Journal: Clin Cancer Res Date: 2017-08-29 Impact factor: 12.531
Authors: Aiwu Ruth He; Roger B Cohen; Crystal S Denlinger; Ashwin Sama; Ariel Birnbaum; Jimmy Hwang; Takami Sato; Nancy Lewis; Michelle Mynderse; Michele Niland; Jennifer Giles; Johan Wallin; Brian Moser; Wei Zhang; Richard Walgren; Elizabeth R Plimack Journal: Oncologist Date: 2019-03-04